GlassScriptPhysician profile
Malika Ammor
NPI 1942828835
$7,957.57
in general payments reported to CMS, 2019-2025
39 companies · $5,959 in 2025
The $5,959 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.07 · 2022: $22.15 · 2023: $882 · 2024: $1,083 · 2025: $5,959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,541 · Travel and Lodging: $2,562 · Education: $821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,541.22 |
| Travel and Lodging | $2,562.00 |
| Education | $821.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $4,586.91 | 2025 | |
| Janssen Biotech, INC. | $360.16 | 2023-2025 | Rybrevant, Darzalex, Tecvayli |
| Exelixis INC. | $356.76 | 2023-2025 | Cabometyx |
| Astellas Pharma US INC | $317.34 | 2023-2025 | Vyloy, Xtandi |
| Celgene Corporation | $253.76 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $216.91 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $166.83 | 2024-2025 | Lynparza, Enhertu, Epanova |
| Revance Therapeutics, INC. | $145.32 | 2025 | Daxxify, Daxi |
| Abbvie INC. | $139.79 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $115.43 | 2024-2025 | Keytruda, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $110.60 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $99.26 | 2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $95.45 | 2024-2025 | |
| Gilead Sciences, INC. | $89.12 | 2023-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $69.65 | 2021-2024 | Eliquis |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $64.47 | 2023-2025 | |
| Daiichi Sankyo INC. | $59.04 | 2025 | Enhertu, Datroway |
| Eisai INC. | $54.70 | 2025 | |
| Genzyme Corporation | $52.73 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.70 | 2024-2025 | Fruzaqla |
| Kite Pharma, INC. | $48.57 | 2024-2025 | Yescarta |
| Glaxosmithkline, LLC. | $46.75 | 2024 | Zejula, Jemperli, Ojjaara |
| Tempus Ai, INC | $45.35 | 2024-2025 | Xt Cdx |
| Legend Biotech USA INC. | $35.78 | 2025 | Carvykti |
| Janssen Pharmaceuticals, INC | $34.96 | 2023-2024 | Rybrevant |
| Beigene USA, INC. | $34.07 | 2024 | Brukinsa |
| Genentech USA, INC. | $28.31 | 2025 | Phesgo |
| Alexion Pharmaceuticals, INC. | $27.23 | 2025 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $26.90 | 2025 | Monoferric |
| Puma Biotechnology, INC. | $26.87 | 2025 | |
| Acrotech Biopharma INC. | $26.84 | 2025 | Beleodaq |
| Fresenius Kabi USA, LLC | $24.92 | 2025 | |
| Karyopharm Therapeutics INC. | $24.68 | 2024 | Xpovio |
| Beone Medicines USA, INC. | $24.45 | 2025 | Tevimbra |
| Cti Biopharma Corp. | $22.15 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.90 | 2025 | |
| Dendreon Pharmaceuticals LLC | $20.55 | 2025 | Provenge |
| Lilly USA, LLC | $17.43 | 2024 | Jaypirca, Verzenio |
| Amgen INC. | $16.93 | 2025 | Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malika Ammor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.